Pilar Ximénez-Embún

Pilar Ximénez-Embún

Auto-generated profile, based on publicly available information

Pilar Ximénez-Embún

Proteomics Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2013 in Immunity
Verified
Journal Article
Closed access
HSHelia B. Schonthaler
Helia B. Schonthaler
JGJuan Guinea-Viniegra
Juan Guinea-Viniegra
SWStefanie K. Wculek
Stefanie K. Wculek
IRIsabel Ruppen
Isabel Ruppen
PXPilar Ximénez-Embún
Pilar Ximénez-Embún
EWErwin F. Wagner
Erwin F. Wagner

28 June 2017 in Nature
Verified
Journal Article
Open access
PDF file
AZAmaia Zabala-Letona
Amaia Zabala-Letona
AAAmaia Arruabarrena-Aristorena
Amaia Arruabarrena-Aristorena
NMNatalia Martín-Martín
Natalia Martín-Martín
SFSonia Fernandez-Ruiz
Sonia Fernandez-Ruiz
JSJames D. Sutherland
James D. Sutherland
ACArkaitz Carracedo
Arkaitz Carracedo
MTOR complex 1 signalling regulates polyamine metabolism and thereby promotes tumorigenesis, through regulation of the stability of a key enzyme, AMD1. The mTOR pathway regulates multiple metabolic pathways in cancers but knowledge of how oncogenic signals regulate polyamine production, which is important in spreading cancer cells, is limited. Arkaitz Carracedo and colleagues add to the existing knowledge. Using a mixture of metabolic analysis techniques, they show that mTOR signalling regulates polyamine metabolism and thereby promotes tumorigenesis through regulation of the stability of a key enzyme, AMD1. They validated this pathway in mouse and human cancer specimens and found that ADM1 is upregulated in prostate cancer specimens with activated mTORC1. This adds to the complexity of cancer cell metabolism and offers new therapeutic avenues. Activation of the PTEN–PI3K–mTORC1 pathway consolidates metabolic programs that sustain cancer cell growth and proliferation1,2. Here we show that mechanistic target of rapamycin complex 1 (mTORC1) regulates polyamine dynamics, a metabolic route that is essential for oncogenicity. By using integrative metabolomics in a mouse model3 and human biopsies4 of prostate cancer, we identify alterations in tumours affecting the production of decarboxylated S-adenosylmethionine (dcSAM) and polyamine synthesis. Mechanistically, this metabolic rewiring stems from mTORC1-dependent regulation of S-adenosylmethionine decarboxylase 1 (AMD1) stability. This novel molecular regulation is validated in mouse and human cancer specimens. AMD1 is upregulated in human prostate cancer with activated mTORC1. Conversely, samples from a clinical trial with the mTORC1 inhibitor everolimus5 exhibit a predominant decrease in AMD1 immunoreactivity that is associated with a decrease in proliferation, in line with the requirement of dcSAM production for oncogenicity. These findings provide fundamental information about the complex regulatory landscape controlled by mTORC1 to integrate and translate growth signals into an oncogenic metabolic program.

25 November 2021 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
Susana Garcia-SilvaSusana Garcia-Silva
Susana Garcia-Silva
ABAlberto Benito-Martín
Alberto Benito-Martín
LNLaura Nogués
Laura Nogués
AHAlberto Hernández-Barranco
Alberto Hernández-Barranco
MMMarina S. Mazariegos
Marina S. Mazariegos
Hector PeinadoHector Peinado
Hector Peinado

1 December 2014 in Cancer Cell
Verified
Journal Article
Closed access
KTKrishna S. Tummala
Krishna S. Tummala
AGAna L. Gomes
Ana L. Gomes
MYMahmut Yilmaz
Mahmut Yilmaz
OGOsvaldo Graña
Osvaldo Graña
LBLatifa Bakiri
Latifa Bakiri
NDNabil Djouder
Nabil Djouder

11 February 2022 in Science Advances
Verified
Journal Article
Open access
SKSheng-Han Kuo
Sheng-Han Kuo
ITInmaculada Tasset
Inmaculada Tasset
MCMelody M. Cheng
Melody M. Cheng
ADAntonio Diaz
Antonio Diaz
MPMing-Kai Pan
Ming-Kai Pan
DSDavid Sulzer
David Sulzer
The most common genetic risk factors for Parkinson’s disease (PD) are a set of heterozygous mutant (MT) alleles of the GBA1 gene that encodes β-glucocerebrosidase (GCase), an enzyme normally trafficked through the ER/Golgi apparatus to the lysosomal lumen. We found that half of the GCase in lysosomes from postmortem human GBA-PD brains was present on the lysosomal surface and that this mislocalization depends on a pentapeptide motif in GCase used to target cytosolic protein for degradation by chaperone-mediated autophagy (CMA). MT GCase at the lysosomal surface inhibits CMA, causing accumulation of CMA substrates including α-synuclein. Single-cell transcriptional analysis and proteomics of brains from GBA-PD patients confirmed reduced CMA activity and proteome changes comparable to those in CMA-deficient mouse brain. Loss of the MT GCase CMA motif rescued primary substantia nigra dopaminergic neurons from MT GCase–induced neuronal death. We conclude that MT GBA1 alleles block CMA function and produce α-synuclein accumulation.

15 July 2019 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
AUAlvaro Conrado Ucero
Alvaro Conrado Ucero
LBLatifa Bakiri
Latifa Bakiri
BRBen Roediger
Ben Roediger
MSMasakatsu Suzuki
Masakatsu Suzuki
MJMaria Jimenez
Maria Jimenez
EWErwin F. Wagner
Erwin F. Wagner
Idiopathic pulmonary fibrosis (IPF) is a deadly disease with limited therapies. Tissue fibrosis is associated with type 2 immune response, although the causal contribution of immune cells is not defined. The AP-1 transcription factor Fra-2 is upregulated in IPF lung sections, and Fra-2 transgenic mice (Fra-2Tg) exhibit spontaneous lung fibrosis. Here, we show that bleomycin-induced lung fibrosis is attenuated upon myeloid inactivation of Fra-2 and aggravated in Fra-2Tg bone marrow chimeras. Type VI collagen (ColVI), a Fra-2 transcriptional target, is upregulated in 3 lung fibrosis models, and macrophages promote myofibroblast activation in vitro in a ColVI- and Fra-2–dependent manner. Fra-2 or ColVI inactivation does not affect macrophage recruitment and alternative activation, suggesting that Fra-2/ColVI specifically controls the paracrine profibrotic activity of macrophages. Importantly, ColVI-KO mice and ColVI-KO bone marrow chimeras are protected from bleomycin-induced lung fibrosis. Therapeutic administration of a Fra-2/AP-1 inhibitor reduces ColVI expression and ameliorates fibrosis in Fra-2Tg mice and in the bleomycin model. Finally, Fra-2 and ColVI positively correlate in IPF patient samples and colocalize in lung macrophages. Therefore, the Fra-2/ColVI profibrotic axis is a promising biomarker and therapeutic target for lung fibrosis and possibly other fibrotic diseases.